Co-Authors
This is a "connection" page, showing publications co-authored by SHERISE DESIREE FERGUSON and JASON HUSE.
Connection Strength
0.749
-
Changes in outcomes and factors associated with survival in melanoma patients with brain metastases. Neuro Oncol. 2023 Jul 06; 25(7):1310-1320.
Score: 0.226
-
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. J Neuropathol Exp Neurol. 2018 06 01; 77(6):437-442.
Score: 0.159
-
Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2024 Jun; 30(6):1787.
Score: 0.060
-
Response of treatment-naive brain metastases to stereotactic radiosurgery. Nat Commun. 2024 May 02; 15(1):3728.
Score: 0.060
-
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 04; 29(4):898-905.
Score: 0.055
-
Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. JCI Insight. 2022 05 09; 7(9).
Score: 0.052
-
CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease. Front Immunol. 2021; 12:745893.
Score: 0.050
-
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
Score: 0.045
-
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019 05; 9(5):628-645.
Score: 0.042